Taysha Gene Therapies, Inc. (TSHA) Income Annual - Discounting Cash Flows
TSHA
Taysha Gene Therapies, Inc.
TSHA (NASDAQ)
Period Ending: LTM
(Last Twelve Months)
2024
12-31
2023
12-31
2022
12-31
2021
12-31
2020
12-31
2019
12-31
Report Filing 2025-11-04 2025-02-26 2024-03-19 2023-03-28 2022-03-31 2021-03-03 2019-12-31
Revenue 6.31 8.33 15.45 2.5 0 0 0
Cost of Revenue 0.286 0 0 2.49 0 0.009 0
Gross Profit 6.02 8.33 15.45 0.015 0 -0.009 0
Operating Expenses 108.2 99.79 87.89 126 173.3 42.99 1.11
Research & Development 76.49 66 56.78 91.17 131.9 31.89 0.987
Selling, General and Administrative 31.66 28.95 30.05 34.87 41.32 11.1 0.128
Other Operating Expenses 0 4.84 1.06 -0 0 0 0
Operating Income -102.1 -91.46 -72.44 -126 -173.3 -43 -1.11
Net Non-Operating Interest 7.98 6.84 -1.43 -3.55 -1.26 0.021 0
Interest Income 8.05 6.94 3.57 0.249 0.172 0.049 0
Interest Expense 0.073 0.102 5 3.8 1.43 0.028 0
Equity & Other Income/(Expense) -5.78 -4.68 -37.7 -36.44 0 -17.03 0
Income Before Tax -99.93 -89.3 -111.6 -166 -174.5 -60.01 -1.11
Income Tax Expense 0 0 0 0 0 0 0
Income Attributable to Non-Controlling Interest 0 0 0 0 0 -17.01 0
Net Income -99.93 -89.3 -111.6 -166 -174.5 -43 -1.11
Depreciation and Amortization 1.15 1.25 1.37 2.49 0.492 0.009 4.46
EBITDA -101 -90.21 -71.07 -123.5 -172.8 -42.99 3.35
Earnings Per Share (EPS) -0.354 -0.357 -0.961 -3.78 -4.64 -3.4 -0.03
Diluted Earnings Per Share -0.354 -0.357 -0.961 -3.78 -4.64 -3.4 -0.03
Weighted Average Shares Outstanding 353.3 250.1 116.1 43.95 37.65 17.67 36.99
Diluted Weighted Average Shares Outstanding 353.3 250.1 116.1 43.95 37.65 17.67 36.99
discounting cash flows home logo

Discounting Cash Flows

Are you finding our services helpful? Review us on trustpilot logo Trustpilot
Have a question? Contact us
Want to become our sponsor?
Check out our Affiliate Program